EUVIMEDEUVIMED entdecken
Crossref

L26/P-744 Serum anti-Müllerian hormone levels before and during the COVID-19 pandemic and vaccination era: a retrospective analysis of 6,741 tests

R. Azaki, Y. Mourad, G. Raad, A. Mourad, F. Fakih, C. Fakih

Human Reproduction · 01.07.2026 · 41 (Supplement_1)

DOI: 10.1093/humrep/deag083.1071 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von R. Azaki und 5 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Study question Are serum anti-Müllerian hormone levels altered across COVID-19 pandemic and vaccination eras, after age adjustment, in a large cohort of infertile women? Summary answer After age adjustment, serum anti-Müllerian hormone levels did not differ significantly across pre-COVID-19, COVID-19 pre-vaccination and vaccination eras. What is known already Anti-Müllerian hormone (AMH) is a key marker of ovarian reserve and declines with advancing age. Since the COVID-19 pandemic, concerns have emerged regarding potential effects of SARS-CoV-2 infection and COVID-19 vaccination on female fertility. Available studies and meta-analyses report heterogeneous findings, with SARS-CoV-2 infection possibly associated with small, transient changes in AMH, whereas COVID-19 vaccination does not appear to adversely affect ovarian reserve. Proposed mechanisms for infection-related changes include systemic inflammation, cytokine-mediated ovarian effects, and temporary disruption of folliculogenesis. However, data from infertile populations, Middle Eastern countries, and age-adjusted analyses over extended periods remain limited. Study design, size, duration This retrospective analysis compared serum anti-Müllerian hormone (AMH) levels across three calendar eras using routine clinical testing data from Lebanon. The COVID-19 pandemic onset was defined according to the World Health Organization declaration, while the vaccination era was defined according to the Lebanese Ministry of Public Health. Infertile women aged 20–45 years with available AMH results and test dates were included. A total of 6,741 AMH tests were analyzed across eras from 2016 to 2026. Participants/materials, setting, methods Infertile women were referred by physicians to a single clinical laboratory in Lebanon for AMH testing. Serum AMH concentrations were measured using the same automated assay throughout the study period. Multivariable linear regression was performed on log-transformed AMH values, adjusting for age and age², with robust (HC3) standard errors. The pre-COVID-19 era served as the reference category. Results were back-transformed and expressed as percent differences with 95% confidence intervals (CI). Main results and the role of chance The median age of the study population was 35 years (interquartile range [IQR] 29–39; range 20–45). In the pre-COVID-19 era, 1,716 tests were recorded (median age 36 years, IQR 31–41), compared with 481 tests in the COVID-19 pre-vaccination era (median age 35 years, IQR 30–40) and 4,544 tests in the vaccination era (median age 34 years, IQR 29–39). Given the strong age dependency of AMH and differences in age distribution across eras, an age-adjusted linear regression analysis was conducted on log-transformed AMH values, adjusting for age and age², using robust (HC3) standard errors and the pre-COVID-19 era as reference. In this model, AMH levels were lower during the COVID-19 pre-vaccination era compared with pre-COVID-19 (−12.4%, 95% CI − 23.2% to − 0.1%; p = 0.048). AMH levels during the vaccination era did not differ from pre-COVID-19 (−2.4%, 95% CI − 9.2% to + 4.8%; p = 0.498). The overall test for an era effect was not statistically significant (p = 0.140). The magnitude of observed differences was small and unlikely to be clinically relevant. Limitations, reasons for caution Limitations include the retrospective, single-centre design, lack of longitudinal follow-up at the individual level, absence of data on COVID-19 infection status and severity, and the possibility of long-term assay drift over the extended study period. Wider implications of the findings These findings provide population-level reassurance that COVID-19 vaccination does not adversely affect ovarian reserve in infertile women and suggest that SARS-CoV-2 infection is unlikely to result in clinically meaningful changes in AMH at a population level. Trial registration number No

Zitieren

APA

Azaki, R., Mourad, Y., Raad, G., Mourad, A., Fakih, F., & Fakih, C. (2026). L26/P-744 Serum anti-Müllerian hormone levels before and during the COVID-19 pandemic and vaccination era: a retrospective analysis of 6,741 tests. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.1071

Vancouver

Azaki R, Mourad Y, Raad G, Mourad A, Fakih F, Fakih C. L26/P-744 Serum anti-Müllerian hormone levels before and during the COVID-19 pandemic and vaccination era: a retrospective analysis of 6,741 tests. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.1071

BibTeX
@article{Azaki2026,
  author = {Azaki, R. and Mourad, Y. and Raad, G. and Mourad, A. and Fakih, F. and Fakih, C.},
  title = {L26/P-744 Serum anti-Müllerian hormone levels before and during the COVID-19 pandemic and vaccination era: a retrospective analysis of 6,741 tests},
  journal = {Human Reproduction},
  year = {2026},
  volume = {41},
  number = {Supplement_1},
  doi = {10.1093/humrep/deag083.1071}
}
Kostenlos starten →